NCT01532726View on ClinicalTrials.gov

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Epilepsy
Interventions
DRUG

ESL

ESL 400/800/1200 mg tablets once daily

Trial Locations (1)

2720-276

Hospital Fernando da Fonseca, Lisbon

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT01532726 - Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) | Biotech Hunter | Biotech Hunter